@drughunter.com
Elinzanetant is a dual NK1R/NK3R antagonist approved in October 2025 for the treatment of moderate to severe VMS due to menopause.
Check out the full case study on Drug Hunter: drughunter.com/molecule/eli...
Check out the full case study on Drug Hunter: drughunter.com/molecule/eli...
November 19, 2025 at 8:59 PM
Elinzanetant is a dual NK1R/NK3R antagonist approved in October 2025 for the treatment of moderate to severe VMS due to menopause.
Check out the full case study on Drug Hunter: drughunter.com/molecule/eli...
Check out the full case study on Drug Hunter: drughunter.com/molecule/eli...
Patent Target Brief: Macrocycles Targeting the LAG3:MHC-II Protein–Protein Interactions | drughunter.com/articles/pat...
Markush structures, representative examples, and biological data are shown in this Patent Target Brief.
Read it on Drug Hunter: drughunter.com/articles/pat...
Markush structures, representative examples, and biological data are shown in this Patent Target Brief.
Read it on Drug Hunter: drughunter.com/articles/pat...
November 17, 2025 at 9:02 PM
Patent Target Brief: Macrocycles Targeting the LAG3:MHC-II Protein–Protein Interactions | drughunter.com/articles/pat...
Markush structures, representative examples, and biological data are shown in this Patent Target Brief.
Read it on Drug Hunter: drughunter.com/articles/pat...
Markush structures, representative examples, and biological data are shown in this Patent Target Brief.
Read it on Drug Hunter: drughunter.com/articles/pat...
Repurposed Sheep Antiparasitic Monepantel (NUZ-001) Enters HEALEY-ALS Platform Trial
An mTOR inhibitor that induces autophagy, Neurizon Therapeutics' NUZ-001, aims to enhance the clearance of aggregation-prone proteins, a hallmark of ALS.
Read it on Drug Hunter: drughunters.com/3LAg9wD
An mTOR inhibitor that induces autophagy, Neurizon Therapeutics' NUZ-001, aims to enhance the clearance of aggregation-prone proteins, a hallmark of ALS.
Read it on Drug Hunter: drughunters.com/3LAg9wD
November 12, 2025 at 11:47 PM
Repurposed Sheep Antiparasitic Monepantel (NUZ-001) Enters HEALEY-ALS Platform Trial
An mTOR inhibitor that induces autophagy, Neurizon Therapeutics' NUZ-001, aims to enhance the clearance of aggregation-prone proteins, a hallmark of ALS.
Read it on Drug Hunter: drughunters.com/3LAg9wD
An mTOR inhibitor that induces autophagy, Neurizon Therapeutics' NUZ-001, aims to enhance the clearance of aggregation-prone proteins, a hallmark of ALS.
Read it on Drug Hunter: drughunters.com/3LAg9wD
Discovery of CHF6333: An Inhaled Neutrophil Elastase Inhibitor | lnkd.in/gKeQPiE6
This case study summarizes the discovery and optimization of CHF6333, as presented by Fabio Rancati at the RSC/SCI 23rd Medicinal Chemistry Symposium.
Read it on Drug Hunter: lnkd.in/gKeQPiE6
This case study summarizes the discovery and optimization of CHF6333, as presented by Fabio Rancati at the RSC/SCI 23rd Medicinal Chemistry Symposium.
Read it on Drug Hunter: lnkd.in/gKeQPiE6
November 12, 2025 at 11:46 PM
Discovery of CHF6333: An Inhaled Neutrophil Elastase Inhibitor | lnkd.in/gKeQPiE6
This case study summarizes the discovery and optimization of CHF6333, as presented by Fabio Rancati at the RSC/SCI 23rd Medicinal Chemistry Symposium.
Read it on Drug Hunter: lnkd.in/gKeQPiE6
This case study summarizes the discovery and optimization of CHF6333, as presented by Fabio Rancati at the RSC/SCI 23rd Medicinal Chemistry Symposium.
Read it on Drug Hunter: lnkd.in/gKeQPiE6
Sepiapterin (Sephience®), an orally bioavailable PAH (phenylalanine hydroxylase) activator from PTC Therapeutics, was approved in July 2025 for the treatment of PKU (phenylketonuria), a condition characterized by neurotoxic Phe (phenylalanine) accumulation.
Read more | drughunters.com/4qXq9Ak
Read more | drughunters.com/4qXq9Ak
November 12, 2025 at 11:45 PM
Sepiapterin (Sephience®), an orally bioavailable PAH (phenylalanine hydroxylase) activator from PTC Therapeutics, was approved in July 2025 for the treatment of PKU (phenylketonuria), a condition characterized by neurotoxic Phe (phenylalanine) accumulation.
Read more | drughunters.com/4qXq9Ak
Read more | drughunters.com/4qXq9Ak
drughunters.com/43lGuVj
Starting January 2026, the Drug Hunter team will release bite-size, <30 minute recorded lectures that distill the modern biopharma industry and drug discovery to essential knowledge for scientists
Sign Up for the Course Navigation Webinar on Dec 9th: drughunters.com/47wNwsR
Starting January 2026, the Drug Hunter team will release bite-size, <30 minute recorded lectures that distill the modern biopharma industry and drug discovery to essential knowledge for scientists
Sign Up for the Course Navigation Webinar on Dec 9th: drughunters.com/47wNwsR
November 12, 2025 at 11:44 PM
drughunters.com/43lGuVj
Starting January 2026, the Drug Hunter team will release bite-size, <30 minute recorded lectures that distill the modern biopharma industry and drug discovery to essential knowledge for scientists
Sign Up for the Course Navigation Webinar on Dec 9th: drughunters.com/47wNwsR
Starting January 2026, the Drug Hunter team will release bite-size, <30 minute recorded lectures that distill the modern biopharma industry and drug discovery to essential knowledge for scientists
Sign Up for the Course Navigation Webinar on Dec 9th: drughunters.com/47wNwsR
Pfizer recently disclosed the discovery journey of PF-07293893, an oral, selective activator of AMPKγ3 developed for the treatment of HFpEF (heart failure with preserved ejection fraction).
Read it on Drug Hunter: drughunter.com/molecule/pf-...
Read it on Drug Hunter: drughunter.com/molecule/pf-...
September 9, 2025 at 9:09 PM
Pfizer recently disclosed the discovery journey of PF-07293893, an oral, selective activator of AMPKγ3 developed for the treatment of HFpEF (heart failure with preserved ejection fraction).
Read it on Drug Hunter: drughunter.com/molecule/pf-...
Read it on Drug Hunter: drughunter.com/molecule/pf-...
Darovasertib is a potential first-in-class, oral pan-PKC inhibitor with both Orphan Drug and Breakthrough Therapy designations and is one of the most clinically advanced targeted therapies for uveal melanoma.
Read it on Drug Hunter: drughunter.com/molecule/dar...
Read it on Drug Hunter: drughunter.com/molecule/dar...
September 9, 2025 at 7:59 PM
Darovasertib is a potential first-in-class, oral pan-PKC inhibitor with both Orphan Drug and Breakthrough Therapy designations and is one of the most clinically advanced targeted therapies for uveal melanoma.
Read it on Drug Hunter: drughunter.com/molecule/dar...
Read it on Drug Hunter: drughunter.com/molecule/dar...
Cracking the Entry Code: CD36 as a Key Receptor for Heterobifunctional Degrader Cellular Uptake
CD36 has recently been identified by Wang et al. as a mediator of cellular uptake for heterobifunctional degraders and other beyond-rule-of-five (bRo5) molecules.
Read more: drughunters.com/464k5MG
CD36 has recently been identified by Wang et al. as a mediator of cellular uptake for heterobifunctional degraders and other beyond-rule-of-five (bRo5) molecules.
Read more: drughunters.com/464k5MG
September 9, 2025 at 7:57 PM
Cracking the Entry Code: CD36 as a Key Receptor for Heterobifunctional Degrader Cellular Uptake
CD36 has recently been identified by Wang et al. as a mediator of cellular uptake for heterobifunctional degraders and other beyond-rule-of-five (bRo5) molecules.
Read more: drughunters.com/464k5MG
CD36 has recently been identified by Wang et al. as a mediator of cellular uptake for heterobifunctional degraders and other beyond-rule-of-five (bRo5) molecules.
Read more: drughunters.com/464k5MG
PF-07853578: Leveraging Chemical Biology to Target a Genetically Defined Driver of MASLD |
PF-07853578 covalently binds to PNPLA3(I148M), displacing it from lipid droplets and promoting its degradation: a novel strategy to restore lipid metabolism.
Read more: drughunter.com/molecule/pf-...
PF-07853578 covalently binds to PNPLA3(I148M), displacing it from lipid droplets and promoting its degradation: a novel strategy to restore lipid metabolism.
Read more: drughunter.com/molecule/pf-...
September 9, 2025 at 7:54 PM
PF-07853578: Leveraging Chemical Biology to Target a Genetically Defined Driver of MASLD |
PF-07853578 covalently binds to PNPLA3(I148M), displacing it from lipid droplets and promoting its degradation: a novel strategy to restore lipid metabolism.
Read more: drughunter.com/molecule/pf-...
PF-07853578 covalently binds to PNPLA3(I148M), displacing it from lipid droplets and promoting its degradation: a novel strategy to restore lipid metabolism.
Read more: drughunter.com/molecule/pf-...
Big Money Bets from June 2025 | drughunters.com/44NDWzb
In our June recap of biopharma deals, we highlight Sanofi acquiring Blueprint for $9.1B, Novo Nordisk partnering with Deep Apple Therapeutics on small molecule obesity drugs, and more!
Read it on Drug Hunter: drughunters.com/44NDWzb
In our June recap of biopharma deals, we highlight Sanofi acquiring Blueprint for $9.1B, Novo Nordisk partnering with Deep Apple Therapeutics on small molecule obesity drugs, and more!
Read it on Drug Hunter: drughunters.com/44NDWzb
July 16, 2025 at 3:22 PM
Big Money Bets from June 2025 | drughunters.com/44NDWzb
In our June recap of biopharma deals, we highlight Sanofi acquiring Blueprint for $9.1B, Novo Nordisk partnering with Deep Apple Therapeutics on small molecule obesity drugs, and more!
Read it on Drug Hunter: drughunters.com/44NDWzb
In our June recap of biopharma deals, we highlight Sanofi acquiring Blueprint for $9.1B, Novo Nordisk partnering with Deep Apple Therapeutics on small molecule obesity drugs, and more!
Read it on Drug Hunter: drughunters.com/44NDWzb
Can Brensocatib Open the Door for Neutrophil-Modulating Drugs? | drughunters.com/3ItDcb2
If approved, brensocatib would not only address a major unmet medical need but also serve as a template for rational neutrophil-targeting drug design.
Read it on Drug Hunter: drughunters.com/3ItDcb2
If approved, brensocatib would not only address a major unmet medical need but also serve as a template for rational neutrophil-targeting drug design.
Read it on Drug Hunter: drughunters.com/3ItDcb2
July 16, 2025 at 3:21 PM
Can Brensocatib Open the Door for Neutrophil-Modulating Drugs? | drughunters.com/3ItDcb2
If approved, brensocatib would not only address a major unmet medical need but also serve as a template for rational neutrophil-targeting drug design.
Read it on Drug Hunter: drughunters.com/3ItDcb2
If approved, brensocatib would not only address a major unmet medical need but also serve as a template for rational neutrophil-targeting drug design.
Read it on Drug Hunter: drughunters.com/3ItDcb2
BBO-10203, A Potential First-in-Class PI3Kα:RAS Protein-Protein Interaction Inhibitor Advances to Phase I Trials | drughunters.com/4ksBKTl
Learn more about BBO-10203, including its discovery, binding mode and much more in our full Drug Hunter case study!
Read more: drughunters.com/4ksBKTl
Learn more about BBO-10203, including its discovery, binding mode and much more in our full Drug Hunter case study!
Read more: drughunters.com/4ksBKTl
July 16, 2025 at 3:20 PM
BBO-10203, A Potential First-in-Class PI3Kα:RAS Protein-Protein Interaction Inhibitor Advances to Phase I Trials | drughunters.com/4ksBKTl
Learn more about BBO-10203, including its discovery, binding mode and much more in our full Drug Hunter case study!
Read more: drughunters.com/4ksBKTl
Learn more about BBO-10203, including its discovery, binding mode and much more in our full Drug Hunter case study!
Read more: drughunters.com/4ksBKTl
JNJ-6640 Reveals Purine Deprivation Strategy Against Drug-Resistant TB
Read it on Drug Hunter:
drughunters.com/3TwdLYr
Read it on Drug Hunter:
drughunters.com/3TwdLYr
July 16, 2025 at 3:18 PM
JNJ-6640 Reveals Purine Deprivation Strategy Against Drug-Resistant TB
Read it on Drug Hunter:
drughunters.com/3TwdLYr
Read it on Drug Hunter:
drughunters.com/3TwdLYr
IRF5 Target Review: Highlighting Two Divergent Approaches to an "Undruggable" Transcription Factor
Read it on Drug Hunter | drughunters.com/4ktbY1l
Read it on Drug Hunter | drughunters.com/4ktbY1l
July 16, 2025 at 3:16 PM
IRF5 Target Review: Highlighting Two Divergent Approaches to an "Undruggable" Transcription Factor
Read it on Drug Hunter | drughunters.com/4ktbY1l
Read it on Drug Hunter | drughunters.com/4ktbY1l
Key Clinical Updates from April 2025
In our recap of April’s clinical updates, we highlight the accelerated approval of Novartis’ atrasentan for immunoglobulin A nephropathy and two oral GLP-1 receptor agonists that are ready to seek approval from the FDA.
Read now | drughunters.com/3ZsymjF
In our recap of April’s clinical updates, we highlight the accelerated approval of Novartis’ atrasentan for immunoglobulin A nephropathy and two oral GLP-1 receptor agonists that are ready to seek approval from the FDA.
Read now | drughunters.com/3ZsymjF
May 19, 2025 at 8:06 PM
Key Clinical Updates from April 2025
In our recap of April’s clinical updates, we highlight the accelerated approval of Novartis’ atrasentan for immunoglobulin A nephropathy and two oral GLP-1 receptor agonists that are ready to seek approval from the FDA.
Read now | drughunters.com/3ZsymjF
In our recap of April’s clinical updates, we highlight the accelerated approval of Novartis’ atrasentan for immunoglobulin A nephropathy and two oral GLP-1 receptor agonists that are ready to seek approval from the FDA.
Read now | drughunters.com/3ZsymjF
Drug Hunter April 2025 Annotated Searchable Patent Table | drughunters.com/4mq3tGE
This month’s collection features an exciting array of innovations, including antiviral agents, LRRK2 degraders, SARM1 inhibitors, CK1α degraders and more!
Read it on Drug Hunter | drughunters.com/4mq3tGE
This month’s collection features an exciting array of innovations, including antiviral agents, LRRK2 degraders, SARM1 inhibitors, CK1α degraders and more!
Read it on Drug Hunter | drughunters.com/4mq3tGE
May 19, 2025 at 8:05 PM
Drug Hunter April 2025 Annotated Searchable Patent Table | drughunters.com/4mq3tGE
This month’s collection features an exciting array of innovations, including antiviral agents, LRRK2 degraders, SARM1 inhibitors, CK1α degraders and more!
Read it on Drug Hunter | drughunters.com/4mq3tGE
This month’s collection features an exciting array of innovations, including antiviral agents, LRRK2 degraders, SARM1 inhibitors, CK1α degraders and more!
Read it on Drug Hunter | drughunters.com/4mq3tGE
Pretzel recently announced initiation of recruitment for a Ph. I study for their undisclosed lead POLγ-targeting asset, PX578, which is likely similar to PZL-A based on their recent patent publications.
Read it on Drug Hunter | drughunters.com/4mpQQeO
Read it on Drug Hunter | drughunters.com/4mpQQeO
May 19, 2025 at 8:04 PM
Pretzel recently announced initiation of recruitment for a Ph. I study for their undisclosed lead POLγ-targeting asset, PX578, which is likely similar to PZL-A based on their recent patent publications.
Read it on Drug Hunter | drughunters.com/4mpQQeO
Read it on Drug Hunter | drughunters.com/4mpQQeO
Bayer Discloses its Selective Dual Factor IIa/Xa Inhibitor, BAY 3389934
In this molecule profile, we highlight the key structural features behind the discovery of BAY 3389934 as a nanomolar-potent, highly soluble compound designed for i.v. administration.
Read now | drughunters.com/4mimeeQ
In this molecule profile, we highlight the key structural features behind the discovery of BAY 3389934 as a nanomolar-potent, highly soluble compound designed for i.v. administration.
Read now | drughunters.com/4mimeeQ
May 19, 2025 at 8:03 PM
Bayer Discloses its Selective Dual Factor IIa/Xa Inhibitor, BAY 3389934
In this molecule profile, we highlight the key structural features behind the discovery of BAY 3389934 as a nanomolar-potent, highly soluble compound designed for i.v. administration.
Read now | drughunters.com/4mimeeQ
In this molecule profile, we highlight the key structural features behind the discovery of BAY 3389934 as a nanomolar-potent, highly soluble compound designed for i.v. administration.
Read now | drughunters.com/4mimeeQ
Now in Ph. I trials for advanced solid tumors, RP-1664 represents a promising test of whether PLK4 inhibition can serve as a precision oncology strategy in TRIM37-amplified cancers such as breast adenocarcinoma and neuroblastoma.
Read more: t.co/YV8luFWahY
Read more: t.co/YV8luFWahY
May 19, 2025 at 8:02 PM
Now in Ph. I trials for advanced solid tumors, RP-1664 represents a promising test of whether PLK4 inhibition can serve as a precision oncology strategy in TRIM37-amplified cancers such as breast adenocarcinoma and neuroblastoma.
Read more: t.co/YV8luFWahY
Read more: t.co/YV8luFWahY
Explore our bioisosteres cheat sheet. Check out how these bioisosteres impact drug properties, improve oral bioavailability, and reduce potential liabilities, ultimately shaping the success of modern therapeutics.
Read more: drughunters.com/4mc2REq
Read more: drughunters.com/4mc2REq
May 19, 2025 at 8:01 PM
Explore our bioisosteres cheat sheet. Check out how these bioisosteres impact drug properties, improve oral bioavailability, and reduce potential liabilities, ultimately shaping the success of modern therapeutics.
Read more: drughunters.com/4mc2REq
Read more: drughunters.com/4mc2REq
In our recap of April biopharma deals, we highlight Nurix licensing a transcription-factor degrader to Sanofi, Prazer Therapeutics raising $20M for targeted protein degraders, and Merck KGaA buying SpringWorks for $3.9B.
Read more: t.co/dvj6F2s4KD
Read more: t.co/dvj6F2s4KD
May 19, 2025 at 8:00 PM
In our recap of April biopharma deals, we highlight Nurix licensing a transcription-factor degrader to Sanofi, Prazer Therapeutics raising $20M for targeted protein degraders, and Merck KGaA buying SpringWorks for $3.9B.
Read more: t.co/dvj6F2s4KD
Read more: t.co/dvj6F2s4KD
BMS-986458 is an orally bioavailable CRBN-mediated heterobifunctional degrader of BCL6 currently in Ph. I/II clinical trials for relapsed/refractory non-Hodgkin lymphomas.
Read it on Drug Hunter | drughunters.com/3RWISvv
Read it on Drug Hunter | drughunters.com/3RWISvv
May 19, 2025 at 8:00 PM
BMS-986458 is an orally bioavailable CRBN-mediated heterobifunctional degrader of BCL6 currently in Ph. I/II clinical trials for relapsed/refractory non-Hodgkin lymphomas.
Read it on Drug Hunter | drughunters.com/3RWISvv
Read it on Drug Hunter | drughunters.com/3RWISvv
GSK and IDEAYA’s (S)-27 is a preclinical, covalent acrylamide inhibitor of WRN helicase—a validated synthetic lethality target in MSI-H tumors.
Read more: drughunters.com/4k3Dvqi
Read more: drughunters.com/4k3Dvqi
May 19, 2025 at 7:59 PM
GSK and IDEAYA’s (S)-27 is a preclinical, covalent acrylamide inhibitor of WRN helicase—a validated synthetic lethality target in MSI-H tumors.
Read more: drughunters.com/4k3Dvqi
Read more: drughunters.com/4k3Dvqi
A Fluorinated Macrobicyclic Antibiotic with Gram-Negative Activity | drughunters.com/43kiq5m
BT-33 is a compelling example of how rigidification and conformational preorganization can revitalize legacy scaffolds for modern antibacterial challenges.
Read more: drughunters.com/43kiq5m
BT-33 is a compelling example of how rigidification and conformational preorganization can revitalize legacy scaffolds for modern antibacterial challenges.
Read more: drughunters.com/43kiq5m
May 19, 2025 at 7:58 PM
A Fluorinated Macrobicyclic Antibiotic with Gram-Negative Activity | drughunters.com/43kiq5m
BT-33 is a compelling example of how rigidification and conformational preorganization can revitalize legacy scaffolds for modern antibacterial challenges.
Read more: drughunters.com/43kiq5m
BT-33 is a compelling example of how rigidification and conformational preorganization can revitalize legacy scaffolds for modern antibacterial challenges.
Read more: drughunters.com/43kiq5m